Encore Global Management LP Takes $2.26 Million Position in Thermo Fisher Scientific Inc. $TMO

Encore Global Management LP bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 4,600 shares of the medical research company’s stock, valued at approximately $2,261,000. Thermo Fisher Scientific makes up 1.6% of Encore Global Management LP’s holdings, making the stock its 25th largest holding.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Assetmark Inc. grew its holdings in Thermo Fisher Scientific by 22.9% during the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after acquiring an additional 7,023 shares during the period. North Dakota State Investment Board bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $7,505,000. Northstar Advisory Group LLC bought a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $3,250,000. Boston Trust Walden Corp lifted its position in shares of Thermo Fisher Scientific by 9.7% during the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock valued at $25,480,000 after acquiring an additional 3,873 shares during the last quarter. Finally, Xponance LLC raised its position in shares of Thermo Fisher Scientific by 8.1% during the fourth quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock worth $34,358,000 after purchasing an additional 4,436 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $577.32 on Wednesday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The firm has a market cap of $214.54 billion, a PE ratio of 31.06, a PEG ratio of 2.28 and a beta of 0.87. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99. The firm’s 50 day moving average price is $498.92 and its 200 day moving average price is $512.05.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same quarter in the prior year, the business posted $4.28 EPS. Thermo Fisher Scientific’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Insider Activity at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on TMO shares. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Wells Fargo & Company reduced their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Stifel Nicolaus dropped their price target on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Finally, Piper Sandler increased their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $617.14.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.